WO2002103355A1 - Agents prophylactiques/remedes pour maladies cardiaques - Google Patents

Agents prophylactiques/remedes pour maladies cardiaques Download PDF

Info

Publication number
WO2002103355A1
WO2002103355A1 PCT/JP2002/006019 JP0206019W WO02103355A1 WO 2002103355 A1 WO2002103355 A1 WO 2002103355A1 JP 0206019 W JP0206019 W JP 0206019W WO 02103355 A1 WO02103355 A1 WO 02103355A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
associated gene
screening
preventives
remedies
Prior art date
Application number
PCT/JP2002/006019
Other languages
English (en)
Japanese (ja)
Inventor
Nobuyuki Koyama
Seiichi Tanida
Koji Yamamoto
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of WO2002103355A1 publication Critical patent/WO2002103355A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne: un procédé de criblage d'un médicament faisant appel à un produit génique associé à une maladie; un anticorps dirigé contre ledit produit génique associé à une maladie; et un ADN antisens inhibant l'expression dudit gène associé à une maladie; une protéine correspondant à la séquence d'aminoacides SEQ ID NO:1 ou une protéine présentant une séquence d'aminoacides sensiblement équivalente à ladite séquence, ainsi que des fragments peptidiques ou des sels d'une telle protéine; un procédé de criblage de médicament faisant appel à ces produits géniques associés à une maladie; un polynucléotide antisens dirigé contre le gène associé à une maladie; des médicaments contenant ce polynucléotide antisens; un anticorps dirigé contre lesdits produits géniques associés à une maladie; des médicaments et des agents diagnostiques contenant cet anticorps; un procédé de criblage d'un composé régulant l'activité des produits géniques associés à une maladie; et des composés obtenus selon le procédé de criblage susmentionné.
PCT/JP2002/006019 2001-06-18 2002-06-17 Agents prophylactiques/remedes pour maladies cardiaques WO2002103355A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001183038 2001-06-18
JP2001-183038 2001-06-18

Publications (1)

Publication Number Publication Date
WO2002103355A1 true WO2002103355A1 (fr) 2002-12-27

Family

ID=19023042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/006019 WO2002103355A1 (fr) 2001-06-18 2002-06-17 Agents prophylactiques/remedes pour maladies cardiaques

Country Status (1)

Country Link
WO (1) WO2002103355A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024571A2 (fr) * 1997-11-10 1999-05-20 Curagen Corporation Genes a expression differentielle en cas d'hypertrophie cardiaque et leur utilisation a des fins de diagnostic et de traitement
WO2001051666A1 (fr) * 2000-01-12 2001-07-19 The General Hospital Corporation Methodes pour diagnostiquer et traiter une maladie du coeur

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024571A2 (fr) * 1997-11-10 1999-05-20 Curagen Corporation Genes a expression differentielle en cas d'hypertrophie cardiaque et leur utilisation a des fins de diagnostic et de traitement
WO2001051666A1 (fr) * 2000-01-12 2001-07-19 The General Hospital Corporation Methodes pour diagnostiquer et traiter une maladie du coeur

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LABEIT SIEGFRIED ET AL.: "Titins: Giant proteins in charge of muscle ultrastructure and elasticity", SCIENCE, vol. 270, 13 October 1995 (1995-10-13), pages 293 - 296, XP002906289 *

Similar Documents

Publication Publication Date Title
WO1995021919A3 (fr) Proteine a activite de thrombopoietine (tpo)
WO2001045638A3 (fr) Compositions et methodes de diagnostic et de traitement des conditions, troubles, ou maladies entrainant la mort cellulaire
ES2170755T3 (es) Conjugados de farmaco antitumoral escindibles por enzimas lisosomales.
EA019397B1 (ru) Антигенсвязывающие белки il-17 рецептора а
FR10C0048I2 (fr) Nouvelle proteine et methode de production associee
WO1998014596A3 (fr) Tyrosine phosphatases proteiques associees a des maladies
DE69831500T2 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
WO2002103355A1 (fr) Agents prophylactiques/remedes pour maladies cardiaques
WO2003076658A3 (fr) Gene de predisposition a la maladie de parkinson idiopathique a apparition tardive
JPH07503128A (ja) ヒト毛様体ニューロン親和性因子の先端欠失型および突然変異タンパク質型の合成と精製
WO2003014703A3 (fr) Acides nucleiques, polypeptides, polymorphismes nucleotidiques simples et techniques d'utilisation de ceux-ci
JPH0257192A (ja) モチリン様ポリペプチドの製法並びにそのための組換えｄｎａ及び発現用プラスミド
US5998579A (en) Epimorphin antagonist and process for producing it
WO1999063094A3 (fr) Sequences nucleotidiques et proteiques gpr1 et methodes y relatives
WO2002029054A1 (fr) Nouvelle proteine, son procede de production et son utilisation
CN1127513C (zh) 具有金属肽酶抑制活性的膦酸衍生物
WO2002062944A2 (fr) Nouveau peptide physiologiquement actif et son utilisation
WO2003022300A1 (fr) Remedes prophylactiques et curatifs contre les maladies des os et des articulations
KR20200033937A (ko) 아다만틸메틸아민 유도체 및 그 의약으로서의 사용
WO2001092491A3 (fr) Phosphatases de proteine de mammifere
WO2003060516A1 (fr) Methode de criblage
WO2003029290A1 (fr) Transporteur de medicament et son utilisation
EP1293511A1 (fr) Facteur de croissance des cellules hepatiques canines
EP1536010A4 (fr) Medicaments destines a la prevention et au traitement du cancer
EP1705189A1 (fr) Facteur de croissance d'hépatocyte féline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP